---
title: "Cowealth Medical China Co.,Ltd. (603122.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603122.SH.md"
symbol: "603122.SH"
name: "Cowealth Medical China Co.,Ltd."
industry: "Health Care Distributors"
datetime: "2026-05-20T22:47:16.823Z"
locales:
  - [en](https://longbridge.com/en/quote/603122.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603122.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603122.SH.md)
---

# Cowealth Medical China Co.,Ltd. (603122.SH)

## Company Overview

Cowealth Medical China Co.,Ltd. operates as a medical company in China. It offers centralized procurement services for in-vitro diagnostic reagents and consumables; platform for decision-making and analysis, commercialization of achievements in medical science and technology; a multi-channel coaxial time audio video imaging platform; and an AI-assisted system for clinical diagnosis. The company was founded in 1997 and is based in Shanghai, China.

| Item | Detail |
|------|--------|
| Industry | Health Care Distributors |
| Exchange | CN Market |
| Website | [ch.cowealth.com](https://ch.cowealth.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.58)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 14 / 23 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -25.09% |  |
| Net Profit YoY | -348.95% |  |
| P/B Ratio | 5.47 |  |
| Dividend Ratio | 0.91% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5722215347.78 |  |
| Revenue | 657546949.74 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -3.25% | D |
| Profit Margin | -5.47% | D |
| Gross Margin | 17.40% | D |
| Revenue YoY | -25.09% | E |
| Net Profit YoY | -348.95% | E |
| Total Assets YoY | -8.92% | E |
| Net Assets YoY | -10.47% | D |
| Cash Flow Margin | 216.01% | B |
| OCF YoY | -25.09% | E |
| Turnover | 0.44 | C |
| Gearing Ratio | 26.02% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Cowealth Medical China Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-25.09%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-348.95%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.47",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.91%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5722215347.78",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "657546949.74",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-3.25%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-5.47%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "17.40%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "-25.09%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-348.95%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-8.92%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-10.47%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "216.01%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-25.09%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.44",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.02%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -155.89 | 26/23 | 199.42 | 191.70 | 185.35 |
| PB | 5.37 | 25/23 | 6.89 | 5.74 | 2.36 |
| PS (TTM) | 8.53 | 25/23 | 10.29 | 8.45 | 3.15 |
| Dividend Yield | 0.92% | 16/23 | 1.82% | 0.84% | 0.65% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | HUADONG MEDICINE (000963.SZ) | B | C | A | B | C | B |
| 02 | SINOPHARM(CNCM LTD) (600511.SH) | C | C | A | C | C | B |
| 03 | TIBET PHARMA (600211.SH) | A | C | C | B | C | B |
| 04 | Shanghai Pharma (601607.SH) | C | C | A | D | C | C |
| 05 | GYBYS (600332.SH) | C | C | A | C | C | C |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603122.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603122.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603122.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603122.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**